Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 38 of the 38 references it cites were found in a registry or an index; 7 of the 9 sources its claims cite were checked for support.
Abstract
BACKGROUND Substantial weight reduction is often associated with loss of muscle mass. Tirzepatide has been associated with significant reductions in body weight in type 2 diabetes trials and a beneficial effect on body fat distribution in the SURPASS-3 MRI substudy. This post-hoc exploratory analysis studied the association of tirzepatide treatment with changes in thigh muscle volume, muscle volume Z score, and muscle fat infiltration, and aimed to contextualise the results using longitudinal MRI data from UK Biobank participants. METHODS SURPASS-3 was a randomised, open-label, parallel-group, phase 3 trial. The multicentre (45 sites) and multinational (eight countries) MRI substudy of SURPASS-3 enrolled insulin-naive adults (aged ≥18 years) with type 2 diabetes who were on treatment with metformin with or without a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, had an HbA1c of 7·0-10·5% (53-91 mmol/mol), a BMI of at least 25 kg/m2, and a fatty liver index of at least 60. Participants were randomly assigned (1:1:1:1) to receive subcutaneous injection once per week of tirzepatide (5, 10, or 15 mg), or subcutaneous injection once per day of titrated insulin degludec. Thigh muscle fat infiltration, muscle volume, and muscle volume Z score (invariant to sex, height, weight, and BMI) were quantified by MRI at baseline and week 52. In this post-hoc analysis, we assessed the differences between mean baseline and week 52 muscle composition values in the tirzepatide groups (poole…
Overview
CoChat Summary
TL;DR
In a post-hoc analysis of the SURPASS-3 MRI substudy, tirzepatide reduced thigh muscle fat infiltration and muscle volume/Z score at 52 weeks in adults with type 2 diabetes, alongside substantial weight loss. Muscle volume loss was similar to UK Biobank population-based estimates for weight change, but myosteatosis reduction was greater than expected.
Key findings
- Among 246 participants with a valid week 52 MRI (tirzepatide 5 mg n=63; 10 mg n=60; 15 mg n=67; insulin degludec n=56), pooled tirzepatide significantly reduced muscle fat infiltration (mean change –0·36 percentage points [95% CI –0·48 to –0·25], p<0·0001), muscle volume (–0·64 L [–0·74 to –0·54], p<0·0001), and muscle volume Z score (–0·22 [–0·29 to –0·15], p<0·0001), with mean relative weight change –10·1% (–11·2 to –9·0, p<0·0001).
- Insulin degludec modestly increased muscle volume (0·16 L [0·01 to 0·31], p=0·043) and bodyweight (3·3% [1·8 to 4·9], p=0·0001), with no significant change in muscle volume Z score (0·06 [–0·06 to 0·18], p=0·35) or muscle fat infiltration (0·03 percentage points [–0·09 to 0·14], p=0·62); all three pooled tirzepatide changes differed significantly from insulin degludec (p<0·01).
- Versus UK Biobank population-based estimates (n=2942), pooled tirzepatide muscle volume change was similar (mean difference –0·04 L [–0·11 to 0·03], p=0·22), while muscle fat infiltration reduction was greater (–0·42 percentage points [–0·54 to –0·31], p<0·0001); tirzepatide 15 mg had a greater muscle volume Z score reduction than estimated (–0·18 [–0·29 to –0·07], p=0·0016).
- Subgroup analyses found older participants (≥60 years) had a significantly larger decrease in muscle volume Z score with tirzepatide than younger participants; no significant differences in muscle composition changes were observed by sex, baseline muscle volume Z score, or baseline muscle fat infiltration categories.
Methods
- Post-hoc exploratory analysis of the SURPASS-3 MRI substudy, a randomised, open-label, parallel-group phase 3 trial at 45 sites in eight countries. Participants were insulin-naive adults with type 2 diabetes on metformin with or without an SGLT-2 inhibitor, HbA1c 7·0–10·5%, BMI ≥25 kg/m², and fatty liver index ≥60, randomly assigned 1:1:1:1 to weekly tirzepatide 5, 10, or 15 mg or daily insulin degludec.
- MRI at baseline and week 52 quantified thigh muscle fat infiltration, muscle volume, and muscle volume Z score. Analyses used modified intention to treat in participants with a valid week 52 MRI; paired t tests assessed within-group changes, and ANCOVA adjusted for baseline value, baseline HbA1c, SGLT-2 inhibitor use, and country compared pooled tirzepatide with insulin degludec.
- Observed changes were compared with population-based estimates from multiple linear regression models fitted to longitudinal MRI data from 2,942 UK Biobank participants; missing values were handled by complete-case analysis, and R version 4.4.0 was used with p<0·05 defining significance.
Limitations
- The paper describes this as a post-hoc exploratory analysis of an open-label trial, and the MRI substudy selected participants with fatty liver index ≥60 and a valid week 52 scan, which limits generalisability.
- Complete-case analysis was used for missing values; only 206 of 246 included participants had complete muscle composition data at both baseline and week 52, which may introduce bias.
- The UK Biobank comparison is observational and used only to contextualise expected weight-related muscle changes, not to establish causality; the provided text is truncated before any formal discussion/limitations section, so author-stated limitations may be incomplete here.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 1 Not checked · 42 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The same scanning procedure, image analyses, and methods of quantification for muscle volume and muscle fat infiltration were used in the SURPASS-3 MRI substudy as in the UK Biobank.15,16”
What the sources say
- Supportedcites [15] Linge, 2018, Body composition profiling in the UK Biobank imaging study, Obesity (Silver Spring) source
The Methods > MRI scanning passage describes the UK Biobank scanning protocol, image-analysis steps, and quantification of thigh muscle volume and muscle fat infiltration. This supports the citation’s role as the source for the UK Biobank methods used for comparison. (LLM, conf=0.88)
- Partly supportedcites [16] Borga, 2020, Reproducibility and repeatability of MRI-based body composition analysis, Magn Reson Med sourceExperimental — accuracy not yet measured
Sections 2.3 (MRI acquisitions) and 2.4 (Body composition analysis; pages unavailable) describe the scanning and analysis methods used to quantify thigh muscle volume and muscle fat infiltration. The paper cites a UK Biobank imaging study, but our copy does not establish that the SURPASS-3 MRI substudy used the same procedures as the UK Biobank. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For pooled tirzepatide, significant reductions were observed from baseline to week 52 in muscle fat infiltration (mean change –0·36 percentage points [95% CI –0·48 to –0·25], p<0·0001)”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but no significant correlation with changes in muscle volume Z score (figure 2B).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Correlation statistics for insulin degludec similarly showed significant correlations of changes in body weight with changes in muscle volume and muscle fat infiltration (figure 2A, C)”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no significant difference in the change in muscle composition with tirzepatide between female and male participants, between participants with a low versus normal or high muscle volume Z score at baseline, or between participants with high versus normal or low muscle fat infiltration at baseline.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 47 claims and every source verdict.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“although incretin-based medications numerically reduce muscle mass, they could also improve muscle quality by reducing intramuscular fat infiltration, as shown with tirzepatide.96”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [96]
The cited source says what the claim attributes to it.
In the citing paper
“a recent study indicated that muscle quality may be improved with tirzepatide therapy, as there is less intramuscular fat infiltration (122).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [122]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“25,26 However, these studies did not report the proportion of muscle mass loss out of total lean mass loss, or change in myosteatosis.”
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042
Attenuation of skeletal muscle and strength in the elderly: the Health ABC Study
Goodpaster, B. H., Carlson, C. L., Visser, M., Kelley, D. E., Scherzinger, A., Harris, T. B., Stamm, E., & Newman, A. B. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.90.6.2157 · Cited by 1,226 · cited 1×
“4–7 However, the use of these technologies to evaluate muscle composition changes in clinical trials is uncommon mainly due to cost and availability.”
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Littlejohns, T. J., Holliday, J., Gibson, L. M., Garratt, S., Oesingmann, N., Alfaro-Almagro, F., Bell, J. D., Boultwood, C., Collins, R., Conroy, M. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15948-9 · Cited by 812
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Self-citationGastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
Self-citationSarcopenic obesity in older adults: a clinical overview
Prado, C. M., Batsis, J. A., Donini, L. M., Gonzalez, M. C., & Siervo, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00943-z · Cited by 355 · cited 1×
“22 Observations from studies in rodents indicate a potential effect of GLP-1 receptor stimulation on microvascular blood flow and glucose transport in skeletal myocytes, with increased supply of oxygen and nutrients, as well as insulin.”
Research works printed but not linked: 1
- Linge, 2023, Two years of wasting with metabolic disorders—initial results on muscle composition from the longitudinal UK Biobank. The Liver Meeting: Boston, Massachusetts; Nov 10–14, 2023, Hepatology, 78, S1
Cited by
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
Pantazopoulos, D., Gouveri, E., Papazoglou, D., & Παπάνας, Ν. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112924 · Cited by 53
New Molecules and Indications for GLP-1 Medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · JAMA · doi:10.1001/jama.2025.14392 · Cited by 50
Billings, L. K., Hsia, S. H., Bays, H. E., Tidemann‐Miller, B., O’Hagan, J., Tham, L. S., Butler, A., KAZDA, C. M., Mather, K. J., & Coşkun, T. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02155-5 · Cited by 47
Metadata
- Authors
- Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., Fernández Landó, L., Bray, R., Linge, J., & Rodriguez, A.
- Affiliations
- British Heart Foundation (GB)
- University Hospitals of Cleveland (US)
- Eli Lilly (United States) (US)
- Linköping University (SE)
- Corresponding author
- Sattar, Naveed
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2025-06
- Volume
- 13
- Issue
- 6
- Pages
- 482-493
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W4409986582
- Cited by
- 131
- References
- 38
- Citations by year
- 2026: 93 · 2025: 38
- FWCI
- 71.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tirzepatide, type 2 diabetes, muscle composition, thigh muscle volume, muscle fat infiltration, insulin degludec, weight loss, body fat distribution, hepatic steatosis, metformin, SGLT2 inhibitors, insulin therapy
- MeSH terms
- Tirzepatide, Adult, Aged, Body Composition, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Magnetic Resonance Imaging, Male, Middle Aged, Muscle, Skeletal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(25)00027-0
- The paper
- Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., Fernández Landó, L., Bray, R., Linge, J., & Rodriguez, A. (2025). Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(25)00027-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.